SELENOH: A Potential Drug Target and Biomarker for Parkinson's Disease

Target Name: SELENOH

NCBI ID: G280636

SELENOH

SELENOH: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder that affects millions of people worldwide. It is characterized by symptoms such as tremors, rigidity, and difficulty with movement, which can significantly impact an individual's quality of life. While several FDA-approved drugs are currently available for the treatment of Parkinson's disease, there is still a need for new and more effective treatments.

Selenoh, also known as Selenoprotein H, is a protein that is expressed in the brain and has been shown to play a role in the development and progression of Parkinson's disease. It is made by the brain and is responsible for maintaining the structure and function of the nervous system.

Selenoh has been shown to interact with several other proteins, including the protein tau. Tau is a protein that is involved in the formation of beta-tubules in the brain and is a hallmark of Parkinson's disease. Studies have shown that selenoh can help to reduce the levels of tau in the brain and improve the structure and function of the nervous system.

In addition to its potential role in the treatment of Parkinson's disease, selenoh has also been shown to be a potential biomarker for the disease. Studies have shown that levels of selenoh are significantly decreased in the brains of people with Parkinson's disease, and that levels of selenoh are highly correlated with the level of tau in the brain. This suggests that selenoh may be a useful biomarker for the diagnosis and progression of Parkinson's disease.

While further research is needed to fully understand the role of selenoh in Parkinson's disease, it is clear that it is an important protein that will be the focus of future research. As such, Selenoh is now a potential drug target for the treatment of Parkinson's disease. Researchers are currently working to develop small molecules that can modulate the levels of selenoh in the brain and to test their effectiveness in treating Parkinson's disease.

While the development of new treatments for Parkinson's disease is a promising direction, it is important to remember that the disease is still a significant public health burden. According to the World Health Organization, over 10 million people worldwide have Parkinson's disease, and this number is expected to reach over 12 million by 2030. As such, it is important to continue to fund research into the development of new treatments for Parkinson's disease in order to improve the lives of those who are affected by the disease.

In conclusion, Selenoh is a protein that has been shown to play a role in the development and progression of Parkinson's disease. It is made by the brain and has been shown to interact with the protein tau, which is involved in the formation of beta-tubules in the brain. In addition, studies have shown that selenoh can be a potential biomarker for the disease and that it may be a useful drug target for the treatment of Parkinson's disease. Further research is needed to fully understand the role of selenoh in Parkinson's disease and to develop effective treatments for the disease.

Protein Name: Selenoprotein H

Functions: May be involved in a redox-related process

The "SELENOH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SELENOH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets